I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Home ESMO 2025
Roche and Genentech at

ESMO 2025

October 17 - October 21
Berlin, Germany
esmo.org
-
Medical Materials
Agenda
Coming soon
07:00 AM
Duration 60mins Berlin, Germany
ESMO treatment (tx) guideline adherence in patients (pts) with lung cancer (LC) with EGFR or ALK (EGFR/ALK) alterations: a WAYFIND-R registry-based study
Dienstmann R.
Oncology | Lung Cancer
Share page
07:25 AM
Duration 10mins Bonn Auditorium
SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab + tiragolumab vs durvalumab in locally advanced, unresectable, stage III non-small cell lung cancer after platinum-based concurrent chemoradiation
Rafal Dziadziuszko
Oncology | Non-Small Cell Lung Cancer
Share page
08:15 AM
Duration 10mins Berlin Auditorium
Giredestrant, an oral selective oestrogen receptor antagonist and degrader, in combination with everolimus in patients with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial
Erica Mayer
Oncology | Her2 Negative Breast Cancer
Share page
10:00 AM
Duration 45mins Berlin, Germany
IMscin001 final analysis: a randomised phase 3 study of subcutaneous (SC) versus intravenous (IV) atezolizumab (atezo) in patients with locally advanced or metastatic non- small cell lung cancer (NSCLC)
Enriqueta Felip, Fiona Young, Luis Herraez-Baranda, Mauricio Burotto, Nadia Tosti, Renzo Alvarez, Teresa Barata, Yotsawaj Runglodvatana, Yovanna Castro, Zanete Zvirbule
Oncology | Non-Small Cell Lung Cancer
Share page
Duration 45mins Berlin, Germany
Machine learning classification of small cell lung cancer using plasma multiomics in IMPower133
M. Reck
Oncology | Small Cell Lung Cancer
Share page
03:15 PM
Duration 5mins Hamburg Auditorium
Patterns of disease progression (PD) and efficacy associated with tumour burden from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC
Paz Ares
Oncology | Small Cell Lung Cancer
Share page
08:55 AM
Duration 10mins Berlin Auditorium
IMbrave152/SKYSCRAPER-14: a phase III study of first-line tiragolumab + atezolizumab + bevacizumab vs placebo + atezolizumab + bevacizumab for patients with untreated locally advanced or metastatic hepatocellular carcinoma
R. Finn
Oncology | Hepatocellular Carcinoma
Share page
10:00 AM
Duration 45mins Berlin, Germany
Safety of atezolizumab with or without tiragolumab following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer (NEOTERIC Study): a randomized, open-label phase II study
Xu J.
Oncology | Rectal cancer
Share page
Duration 45mins Berlin, Germany
Phase I study of ERY974 + atezolizumab (atezo) + bevacizumab (bev) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)
Ann-Lii Cheng Hideki Ueno, Sadahisa Ogasawara, Chia-Jui Yen, Masatoshi Kudo, Teng-Yu Lee, Masafumi Ikeda, Yin-Hsun Feng, Chao-Hung Hung, Makoto Ueno, Daisuke Shimizu, Hitomi Takeshita, Hiroaki Tomita, Mikiko Nakamura, Chika Ogami, Chun-Yen Lin
Oncology | Hepatocellular Carcinoma
Share page
Duration 45mins Berlin, Germany
Clinical outcome of patients with sporadic vs Lynch syndrome-related stage III colon cancers with deficient mismatch repair (dMMR) treated in a randomized trial of adjuvant FOLFOX alone or combined with atezolizumab (Alliance A021502; ATOMIC)
Sinicrope F.A.
Oncology | Colorectal Cancer
Share page
02:45 PM
Duration 5mins Cologne Auditorium
SKYSCRAPER-09: Phase 2, non-comparative, randomised study of tiragolumab + atezolizumab and placebo + atezolizumab as first-line treatment in patients with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck(atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)
Amanda Psyrri, Amaury Daste, Arunee Dechaphunkul, Ching-Yun Hsieh, Chipman R Stroud, Christina Matheny, Christophe Le Tourneau, Deborah Wong, Denise Bradley (Richardson), Floriane Alias, JEROME FAYETTE, Kevin Harrington, Maura Gillison, Melissa Johnson, Nuttapong Ngamphaiboon, Se Hoon Lee, Tien Hoang, Wei Zhang, Yibing Yan
Oncology | Squamous Cell Cancer
Share page
10:00 AM
Duration 45mins Berlin, Germany
Phase I/Ib trial of inavolisib▼ (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)
Philippe L. Bedard
Oncology | Breast Cancer
Share page
Duration 45mins Berlin, Germany
Interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A Phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Hope S. Rugo
Oncology | Estrogen Receptor Positive Breast Cancer
Share page
12:50 PM
Duration 5mins Hamburg Auditorium
Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)
Agata Higgerson, Andres Cardona, Astrid Scalori, Benjamin Solomon, Dae Ho Lee, FABRICE BARLESI, FILIPPO DE MARINIS, Hidehito Horinouchi, Igor Bondarenko, Jin Seok Ahn, Jong-Seok Lee, Makoto Nishio, Maria Rita Migliorino, Maximilian Hochmair, Rafał Dziadziuszko, Tingting Xu, Virginia McNally, Weimin Mao, Wenzhao Zhong, Yi-Long Wu
Oncology | Non-Small Cell Lung Cancer
Share page

© 2025 Genentech USA, Inc. All rights reserved. This site is intended for US HCPs only.

Learn more about MEDICALLY